27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Globally, ADOD incidence, prevalence, and mortality increased significantly between 1990 and 2021 (156.54%, 160.81%, and 194.39%, respectively). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Globally, 9.84 million cases of ADOD occurred in 2021, with 1.95 million ADOD-related deaths, causing 36.33 million DALYs. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Despite progress in involving people living with dementia in health research, disparities remain, particularly in the field of health economics and outcomes research, where excessive reliance on proxy reports from care partners or healthcare professionals persists even when people are capable of self-reporting, leading to inequitable inclusion. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Using data from South Korea’s 2018 teleconsultation pilot program involving 1232 patients, the analysis revealed that teleconsultation reduced societal costs per consultation by USD 7.92 for chronic diseases, USD 27.30 for dementia care, and USD 9.61 for rehabilitation. 4 key findings →
Participants: 1,232 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 53 stakeholders participated in focus groups and engagement sessions. 5 key findings →
Participants: 53 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The mean (SD) age of PWD was 81 (8.1) years; 45% were women, 33% Black, and 15% Hispanic. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In 2021, dementia accounted for 56.9 million global cases, 2.0 million deaths, and 36.3 million DALYs. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The global age-standardised DALY rates of ADRDs per 100 000 population slightly increased from 1331.59 (95% confidence interval (CI) = 881.57, 1781.61) in 1990 to 1347.24 (95% CI = 906.36, 1788.12) in 2021, with an AAPC of 0.04% (95% CI = 0.02, 0.05). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Incorporating RHR into the CAIDE model significantly improved predictive accuracy across Black African, Asian, White, and Native Hawaiian populations (mean AUC range: 0.80-0.91). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Three common protein isoforms of apolipoprotein E (apoE), encoded by the epsilon2, epsilon3, and epsilon4 alleles of the APOE gene, differ in their association with cardiovascular and Alzheimer's disease risk. 2 key findings →
Participants: 48 Evidence: low
Full summary, score breakdown and related studies → Original source
In 2019, the global VSL-based economic burden of ADRDs was an estimated $2.8 trillion. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
China's population has rapidly aged over the recent decades of social and economic development as neurodegenerative disorders have proliferated, especially Alzheimer's disease (AD) and related dementias (ADRD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Individuals from minoritized racial/ethnic groups face a disproportionate burden of Alzheimer's disease and related dementias. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The burden of neurological disease is increasing globally. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Older adults classified with dementia were more likely to drop out of the labor force and become poor than similar older adults without dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia is a major health concern in society, particularly in the aging population. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
During follow up (mean 11.1 years), 13% of Veterans developed dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Compared to White participants, Black, Hispanic, and Asian participants reported taking fewer total medications (incidence rate ratio [IRR] ± standard error[SE] = 0.903 ± 0.017, 0.875 ± 0.021, and 0.912 ± 0.041, respectively, all p < 0.01). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Washington University School of Medicine Knight Alzheimer Disease Research Center's "African American Participation in Alzheimer Disease Research: Effective Strategies" Workshop convened to address a major limitation of the ongoing scientific progress regarding Alzheimer's disease and related dementias (ADRD): participants in most ADRD research programs overwhelmingly have been limited to non-Hispanic white persons, thus precluding knowledge as to how ADRD may be represented in non-white individuals. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Significant disparities in symptom severity reported by Alzheimer's caretakers were observed among the racial groups analyzed. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) disproportionately affects certain racial and ethnic subgroups, such as African American/Black and Hispanic adults. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Overly restrictive clinical trial eligibility criteria can reduce generalizability, slow enrollment, and disproportionately exclude historically underrepresented populations. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Patients had a mean age of 70.4 (±6.6) years and 97.8% were men. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Participants indicated skepticism regarding the use of precision medicine in their communities. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The precursor of the non-Abeta-component of Alzheimer's disease (AD) amyloid (NACP, alpha-synuclein) aggregates into insoluble filaments of Lewy bodies (LBs) in Parkinson's disease (PD) and dementia with LBs (DLB). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →